Check how courts have cited this case. Use our free citator for the most current treatment.
No. 10145361
United States Court of Appeals for the Ninth Circuit
H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc.
No. 10145361 · Decided October 18, 2024
No. 10145361·Ninth Circuit · 2024·
FlawFinder last updated this page Apr. 2, 2026
Case Details
Court
United States Court of Appeals for the Ninth Circuit
Decided
October 18, 2024
Citation
No. 10145361
Disposition
See opinion text.
Full Opinion
NOT FOR PUBLICATION FILED
UNITED STATES COURT OF APPEALS OCT 18 2024
MOLLY C. DWYER, CLERK
U.S. COURT OF APPEALS
FOR THE NINTH CIRCUIT
H&H PHARMACEUTICALS, LLC, No. 23-16179
Plaintiff-Appellant, D.C. No.
2:16-cv-02148-GMN-VCF
v.
CHATTEM CHEMICALS, INC.; SUN MEMORANDUM*
PHARMACEUTICALS INDUSTRIES,
INC.,
Defendants-Appellees.
Appeal from the United States District Court
for the District of Nevada
Gloria M. Navarro, District Judge, Presiding
Submitted October 10, 2024**
Las Vegas, Nevada
Before: BEA, BENNETT, and MILLER, Circuit Judges.
Plaintiff H&H Pharmaceuticals, LLC (“H&H”) sued Chattem Chemicals, Inc.
(“Chattem”) and Sun Pharmaceuticals Industries, Inc. (“Defendants”) for breach of
*
This disposition is not appropriate for publication and is not precedent
except as provided by Ninth Circuit Rule 36-3.
**
The panel unanimously concludes this case is suitable for decision
without oral argument. See Fed. R. App. P. 34(a)(2).
a “Settlement Agreement” entered into between H&H and Chattem. 1 After H&H
appealed the district court’s grant of summary judgment in favor of Defendants, we
“affirm[ed] in part, vacate[d] in part, and remand[ed] to the district court for further
proceedings consistent with [the] memorandum.” H&H Pharms., LLC v. Chattem
Chems., Inc., No. 23-15055, 2024 WL 1734134, at *1 (9th Cir. Apr. 23, 2024)
(“H&H I”).
Before we decided H&H I, the district court, on Defendants’ motion, entered
an order awarding Defendants $213,515.60 in attorneys’ fees and $21,649.25 in
costs. H&H appealed. Exercising jurisdiction under 28 U.S.C. § 1291, we vacate
the district court’s order and remand.
Section 28 of the Settlement Agreement provides:
The parties agree that if suit is instituted alleging a breach of this
[Settlement] Agreement, a breach of the NDA and/or a
misappropriation of [H&H’s] Trade Secrets that the prevailing party
shall have its fees and expenses, including attorneys’ fees, paid by
the losing party.
In H&H I, we “agree[d] with the district court that H&H failed to present a triable
issue of fact on the required element of damage to withstand summary judgment on
1
H&H and Chattem initially entered into an agreement to commercialize H&H’s
confidential technology for the parties’ mutual benefit. The parties signed a non-
disclosure agreement (“NDA”) to guarantee that Chattem would maintain H&H’s
confidential technology in confidence. The NDA became the subject of H&H’s first
lawsuit against Chattem in 2007. The parties settled that lawsuit and signed the
“Settlement Agreement.”
2
its standalone contract claims against Chattem.” Id. at *2. But we also held that the
district court erred with respect to H&H’s other claims because Nevada’s Uniform
Trade Secrets Act (UTSA), Nev. Rev. Stat. § 600A.090, “displaced H&H’s
common-law causes of action for tortious breach of the implied covenant of good
faith and fair dealing, for breach of fiduciary duty, for constructive fraud, for
fraudulent concealment, for fraudulent misrepresentation, for negligent
misrepresentation, for negligence, for unjust enrichment, and for civil conspiracy.”
Id. “Given that the district court failed to recognize the displacing effect of the
UTSA . . . , we vacate[d] the district court’s judgment with respect to those causes
of action and remand[ed] to the district court to determine, in the first instance,
whether H&H has already adequately pled a statutory UTSA claim . . . and if not,
whether H&H should be granted leave to replead such a claim.” Id. We determined
that each party in H&H I should bear its own costs on appeal. Id. at *3.
Because of our decision in H&H I, Defendants are no longer a “prevailing
party” under the Settlement Agreement. See Hopkins v. City of Sierra Vista, 931
F.2d 524, 529 (9th Cir. 1991) (“Because we reverse and remand for further
proceedings on the merits, there is no prevailing party and we must also reverse the
district court’s award of attorneys’ fees.”); Spencer v. Klementi, 466 P.3d 1241, 1249
(Nev. 2020) (“Because [respondents] are no longer prevailing parties on
[appellant’s] defamation claim, we vacate the awards of attorney fees in their
3
favor.”). This is so even though we reversed only in part. See, e.g., Long v. Coast
Resorts, Inc., 267 F.3d 918, 925 (9th Cir. 2001).
Defendants argue that “if the judgment below is reversed in part as to claims
other than the purported breach of the Settlement Agreement . . . [Defendants] are
still entitled to their attorneys’ fees and costs.” This is not so. The “suit”
contemplated by the Settlement Agreement encompasses not just the contractual
claims, which we affirmed, but also any allegation of “a misappropriation of
[H&H’s] Trade Secrets,” which we vacated and remanded. On remand, Defendants
may end up as the prevailing party. But as of now, Defendants are no longer the
prevailing party. 2
VACATED AND REMANDED.
2
The parties shall bear their own costs on appeal.
4
Plain English Summary
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS OCT 18 2024 MOLLY C.
Key Points
01NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS OCT 18 2024 MOLLY C.
02COURT OF APPEALS FOR THE NINTH CIRCUIT H&H PHARMACEUTICALS, LLC, No.
03CHATTEM CHEMICALS, INC.; SUN MEMORANDUM* PHARMACEUTICALS INDUSTRIES, INC., Defendants-Appellees.
04Navarro, District Judge, Presiding Submitted October 10, 2024** Las Vegas, Nevada Before: BEA, BENNETT, and MILLER, Circuit Judges.
Frequently Asked Questions
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS OCT 18 2024 MOLLY C.
FlawCheck shows no negative treatment for H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc. in the current circuit citation data.
This case was decided on October 18, 2024.
Use the citation No. 10145361 and verify it against the official reporter before filing.